FAST California
Meet the 2025 FAST Fall cohort—twelve innovative life sciences startups developing impactful solutions. These companies will spend the next several weeks working with our curated network of advisors to develop a compelling commercialization strategy.
Join us on December 10th for our Innovation Showcase where these founders will present to an audience of investors and collaboration partners. Learn more here!
Aikium
Aikium is building the world’s largest protein–protein interaction datasets with AI and synthetic biology, creating the “Scale AI for Biology” data layer to unlock undruggable targets and enable next-generation biologics.
Eswar Iyer, PhD | Co-Founder & CEO
[email protected]
AivoCode
AivoCode Inc. is a preclinical biotechnology company developing novel therapeutics to address critical unmet needs in neuroprotection and neurodegeneration.
Aman Mann, PhD | Co-Founder & CEO
[email protected]
Brainstorm Therapeutics
BrainStorm Therapeutics is a precision neuroscience company using patient-derived brain organoids and AI to discover and develop targeted therapies for complex brain diseases with greater speed, accuracy, and clinical relevance.
www.brainstormtherapeutics.org
Robert Fremeau, PhD | Founder and CEO
[email protected]
Butterfly Biosciences
High Quality Care for All Women. Our goal is transformation of gynecologic care through an image-based diagnostic that will improve precision of diagnosis, lower the time to diagnosis and prevent suffering for millions of women on a yearly basis.
Moses Cesario | CEO
[email protected]
Crafton Bio
Crafton Biotechnology, a privately-held mRNA drug developer, is advancing a pipeline of novel vaccines and therapeutics powered by its proprietary platforms—PureCap®, a leading mRNA Cap2 analog enabling ultra-pure, GMP-grade mRNA with superior protein expression, and CRAFT™, which allows rapid, DNA-free mRNA synthesis with chemical modifications—with a COVID program entering the clinic in 2026 and additional discovery-stage assets in oncology and beyond.
Kelvin Chan, PhD | CTO & CBO
[email protected]
DINYA DNA
DINYA DNA is building the next generation of DNA synthesis technology. By directly synthesizing long dsDNA using our novel enzymatic synthesis platform, DINYA offers unprecedented turnaround, longer sequences, and improved complexity for all.
Ben Lerman | Co-Founder & CEO
[email protected]
DM Therapeutics
DM Therapeutics is developing Dark Matter DNA, a non-viral, fully synthetic gene therapy platform enabling delivery of large genes and precise, nuclease-free editing, designed for durable efficacy, scalable manufacturing, and broad therapeutic applications.
Jake Lesnik | CEO & Co-Founder
[email protected]
Editpep
Editpep is a pre-clinical therapeutics company advancing biologic genome editing therapeutics, leveraging a highly unique, non-viral delivery technology which unlocks CRISPR’s potential for treating genetic brain diseases.
Dana Foss, PhD | CEO
[email protected]
NeuroSentry
NeuroSentry is revolutionizing stroke detection with innovative EEG-based software technology, providing real-time analytics and intuitive solutions for non-expert users across diverse clinical settings.
Mauro Caffarelli, MD | Co-Founder
[email protected]
Rohit Jain, PhD | Co-Founder
[email protected]
Opal Therapeutics
Opal Therapeutics is building the first “Uterus-in-a-dish” platform to replace outdated, irrelevant mouse models with lab-grown uterine organoids that deliver human data from day one, unlocking more accurate drug discovery, better outcomes for women, and major cost savings for pharma.
Morgan Stanton, PhD | CEO
[email protected]
QUM Therapeutics
QUM Therapeutics is developing a novel, next-generation T cell engager platform that minimizes cytokine release while maximizing anti-tumor efficacy.
Jaehak Oh, PhD
[email protected]
Seen Therapeutics
Seen Therapeutics is uncovering the invisible cancer surfaceome to develop precise and effective immunotherapies.
Althea Stillman, PhD
[email protected]